Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Ferrières, J; Lautsch, D; Gitt, AK; De Ferrari, G; Toplak, H; Elisaf, M; Drexel, H; Horack, M; Baxter, C; Ambegaonkar, B; Brudi, P; Toth, PP.
Body Mass Index impacts the choice of lipid lowering treatment with no correlation to blood cholesterol - findings from 52,916 patients in the Dyslipidemia International Study (DYSIS).
Diabetes Obes Metab. 2018;
PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Toplak Hermann

Dimensions Citations:

Plum Analytics:
A high body mass index (BMI) is associated with increased cardiovascular risk. We sought to identify whether BMI influences the choice of lipid lowering treatment in a large, real world cohort of 52,916 patients treated with statins. The Dyslipidemia International Study (DYSIS) is a cross-sectional, observational, multicenter study in statin-treated patients≥45 years of age from 30 countries. 1.1% were underweight (BMI<18.5 kg/m2 ), 33.1% had normal weight (BMI 18.5 to 24.9 kg/m2 ), 41.5% were overweight (BMI 25 to 29.9 kg/m2 ), 17.1% had class I obesity (BMI 30.0 to 34.9 kg/m2 ), 5.0% had class II obesity (BMI 35 to 39.9 kg/m2 ), and 2.1% had class III obesity (≥40 kg/m2 ). BMI correlated with high-density lipoprotein cholesterol (HDL-C) and triglycerides (Spearman's ρ: -0.147 and 0.170, respectively; p < 0.0001 for both); however, there was no correlation with low-density lipoprotein cholesterol (LDL-C; ρ: 0.003; p=0.51). Statin intensity increased with increasing BMI (ρ: 0.13; p<0.001), an association that held after adjustment for comorbidities (OR: 2.4; 95% CI: 2.0-3.0) on BMI ≥30 kg/m2 for atorvastatin equivalent ≥40mg/day. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

© Meduni Graz Impressum